InSite Vision to Webcast Annual Meeting of Stockholders on May 29, 2013
InSite Vision to Webcast Annual Meeting of Stockholders on May 29, 2013
ALAMEDA, Calif.--(BUSINESS WIRE)-- InSite Vision Incorporated (OTCBB: INSV) will hold its Annual Meeting of Stockholders at 10:00 a.m. Pacific Time on Wednesday, May 29, 2013 at the company's headquarters at 965 Atlantic Avenue, Alameda, California. Company management will host a live webcast of the meeting, including a corporate presentation, available on the Investor Relations page of the company's website (www.insitevision.com). Interested parties may pre-register for the webcast of the meeting and corporate presentation via the following link: http://phx.corporate-ir.net/phoenix.zhtml?c=86061&p=irol-EventDetails&EventId=4926231. For those who miss the live broadcast, an archived replay will be available shortly thereafter.
Analysts and investors can participate in the Annual Meeting via conference call by dialing 888-679-8033 for domestic callers and 617-213-4846 for international callers and entering the pass code 98249449. An audio-only replay will be available via phone following the conclusion of the meeting for two weeks by dialing 888-286-8010 for domestic callers and 617-801-6888 for international callers with the pass code 37737478.
About InSite Vision
InSite Vision is advancing new ophthalmologic products for unmet eye care needs based on its innovative DuraSite® platform technologies. The DuraSite and DuraSite 2 drug delivery systems extend the duration of drug retention on the surface of the eye, thereby reducing the frequency of treatment and improving the efficacy of topical drugs.
The DuraSite platform is currently leveraged in two commercial products for the treatment of bacterial eye infections, AzaSite® (azithromycin ophthalmic solution) 1%, marketed in the U.S. by Merck, and Besivance® (besifloxacin ophthalmic suspension) 0.6%, marketed by Bausch + Lomb. InSite Vision is also advancing three novel ophthalmic therapeutics through Phase 3 clinical studies: AzaSite Plus™ and DexaSite™ for the treatment of eye inflammation, and BromSite™ for pain and inflammation associated with ocular surgery. For further information on InSite Vision, please visit www.insitevision.com.
InSite Vision
Louis Drapeau, 510-747-1220
Chief Financial Officer
mail@insite.com
Media and Investor inquiries
or
BCC Partners
Michelle Corral, 415-794-8662
Karen L. Bergman, 650-575-1509
KEYWORDS: United States North America California
INDUSTRY KEYWORDS:
The article InSite Vision to Webcast Annual Meeting of Stockholders on May 29, 2013 originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
